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ABSTRACT 
Background: Preclinical evidences support the hypothesis of a serotonergic dysfunction in 
alcohol preference. In human, studies have demonstrated a serotonergic hypoactivity in 
alcoholism. However, little is known about the role of 5-HT1A receptors.  
Methods: We assessed the hormonal (prolactin and cortisol) responses to flesinoxan (a highly 
potent and selective 5-HT1A agonist) in 12 male inpatients meeting DSM-IV criteria for alcohol 
dependence, 3 weeks after the last reported use of alcohol and antidepressants. These patients 
were compared to 10 male controls. 
Results: There was a highly significant difference between alcoholic patients and controls for the 
area under the curve relative (AUCr) values of prolactin responses. AUCr values of cortisol 
responses to flesinoxan showed a trend towards lower values in alcoholics compared to 
controls. 
Conclusion: These results support the implication of the serotonergic system, and particularly a 
decreased sensitivity of post-synaptic 5-HT1A receptors, in alcoholism.  
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Several preclinical evidences support the hypothesis of biological vulnerabilities in the 
pathogenesis of alcohol dependence. Serotonin (5-hydroxytriptamine, 5-HT), as well as many 
other neurotransmitters, is thought to play a major role in pathologic drinking (Koob and 
Roberts, 1999). In animal as well as in human studies, important advances have been made in 
clarifying the role of 5-HT as a central mediator of alcohol consumption, suggesting an impaired 
5-HT activity in alcohol preference. Furthermore, many studies have also highlighted the 
possible modulation of behavioral components in some alcoholic patients by brain 5-HT 
(Pettinati et al., 2000). 
As for the specific involvement of 5-HT1A receptors in alcohol dependence, few data are 
available. Animal studies have shown to be controversial. A selective reduction in alcohol intake 
and dopamine release was indeed observed in alcohol-drinking rats treated with the partial 5-
HT1A agonist ipsapirone (Yoshimoto and McBride, 1992), or the 5-HT1A agonist 8-OH-DPAT 
(Schreiber et al., 1993). Furthermore, the administration of the presynaptic autoreceptor acting 
5-HT1A antagonist WAY-100635, which increases 5-HT neurotransmission, was shown to 
reduce alcohol consumption in rodents (Zhou et al., 1998). Yet, another study using 8-OH-DPAT 
injections specifically in the median or dorsal raphe nucleus showed an enhanced alcohol intake 
(Tomkins et al., 1994). In humans, post-mortem studies have shown a reduction in the 
expression of the 5-HT1A receptors in brains of alcohol-dependent deceased patients (Dillon et 
al., 1991). Pharmacological evidence also supports the implication of a low 5-HT1A activity in 
alcoholism. In non human primates as well as in men, the partial 5-HT1A agonist buspirone 
seemed to decrease alcohol intake. However, buspirone may be efficient only when alcoholism is 
associated with anxiety (Tollefson et al., 1990). 
In order to assess the specific implication of 5-HT1A receptors in alcohol preference, we 
performed a preliminary study in a small group of alcoholic patients, using the prolactin (PRL) 
and the cortisol responses to flesinoxan challenge test. Flesinoxan is a highly potent and 
selective 5-HT1A agonist that was shown to induce a significant and dose-dependant increase in 
PRL and cortisol in healthy volunteers (Pitchot et al., 1995; Seletti et al., 1995). 
Methods and materials 
SUBJECTS 
The study was carried out in 12 male inpatients (mean age 47.1 years; S.D. =10) hospitalized in 
the Department of Psychiatry of the University Hospital of Liège (Belgium) for alcohol 
detoxification. They all met DSM-IV criteria for alcohol-dependence, the mean age of onset of 
alcohol-dependence being 27.0 years (S.D. = 7.4). No history of suicide was recorded. Patients 
scored less than 7 on the 17-item Hamilton depression scale and were all medication-free at the 
time of the study, three weeks after the last reported use of alcohol or antidepressants. The 
washout was supervised during their hospitalization. Subjects were compared to 10 male 
controls, comparable for age (mean age 43.8 years; S.D. = 7.6) and weight (72.9 kg; S.D. = 8.5 in 
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the alcohol group, 73.5 kg; S.D. =8.6 in the control group) recruited among the staff of the 
University Hospital of Liège, who all underwent a medical interview to exclude psychiatric or 
somatic disorders. Moreover, none had a family history of alcohol-dependence. 
NEUROENDOCRINE PROCEDURE 
The flesinoxan challenge test was performed at 0830h after an overnight fast in the Department 
of Psychiatry of the Liège University Hospital. Flesinoxan (1 mg/70 kg of body weight), diluted 
in saline solution to obtain 20 ml, was injected IV in 10 min, and blood samples of 10 ml were 
collected 30 min and immediately before the injection, and 15, 30, 60, 90 and 120 min after the 
injection. Prolactin and cortisol were measured by radioimmunoassay (RIA) with intra-assay 
and inter-assay coefficients of variation of 10.0 and 10.0% for PRL (detection limit = 10 μ/l) and 
4.3 and 8.3% for cortisol (detection limit = 5 μg/l) (Ansseau et al., 1984). Hormonal responses 
following flesinoxan were assessed by the relative value of the area under the curve (AUCr) 
between the injection and the last blood sample. Calculation is based upon geometrical methods, 
and the relative value is obtained after the subtraction of baseline value from the AUC. This 
avoids any baseline effect on hormonal response values. 
STATISTICAL ANALYSES 
Statistical analyses were performed using Statistica for Windows, Version 5.1 (Statsoft, Tulsa, 
OK, 1996). A simple ANOVA was performed to compare the AUCr for prolactin and cortisol 
responses between alcoholics and controls. Data were also analyzed by a 2 (group) by 6 (time) 
mixed ANOVA design with time as the repeated measure, while post hoc comparisons were 
made with the Tukey’s honestly significant difference (HSD) test (Spjotvoll – Stoline 
modification for unequal ns). 
Results 
There was a highly significant difference (F1,20 = 8.58, p > 0.008) between alcoholic patients and 
controls for the area under the curve relative values of prolactin responses (Fig. 1): 5232 μIU 
min/l (SD =7734) vs 16 233 μIU min/l (SD = 9892) whereas no difference was found in PRL 
levels at baseline between alcoholics and controls (139.7 μIU, SD = 53.42 vs 146.4 μIU, SD = 
76.83). Furthermore, repeated measures analysis of PRL responses to flesinoxan showed a 
significant effect for group (F[1,20] = 5.42, p < .03), a highly significant effect for time (F[5,100] 
= 16.1, p < .001) and a group-by-time interaction (F[5,100] = 2.9, p < .01). Fig. 1 shows the 
comprehensive profile of PRL response to flesinoxan as well as post hoc differences at each time.  
Cortisol at baseline was not statistically different in the two groups (121.7 μg, SD = 43.5 in 
alcoholics vs 114.6 μg, SD = 38.25 in controls), but AUCr values of cortisol responses to 
flesinoxan were lower in alcoholics compared to controls (Fig. 2), only at a trend level (F1,20 = 
3.99, p < 0.059): minus 1 478 μg min/l (SD = 2927) vs 2424 μg min/l (SD = 5973). Repeated 
measures analysis of cortisol responses to flesinoxan showed no significant effect for group nor 
for time but there was a highly significant group-by-time interaction (F[5,100] = 3.36, p < .008). 
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Fig. 2 shows the comprehensive profile of cortisol response to flesinoxan. No significant 
differences were found in post hoc comparisons. 
 
 
Fig. 1. Prolactin response to flesinoxan among Alcoholics (N =12) and Controls (N =10). Post Hoc Tukey HSD 
comparisons : ∗ p < .05 ; ∗∗ p <.01. Bars indicate Standard Error of Means (SEM). 
 
 
Fig. 2. Cortisol response to flesinoxan among Alcoholics (N =12) and Controls (N =10). Post Hoc Tukey HSD 
comparisons : ∗ p < .05 ; ∗∗ p <.01. Bars indicate Standard Error of Means (SEM). 
Discussion 
 
This study confirmed the possible implication of 5-HT1A receptors in alcoholism, and the 
usefulness of the flesinoxan challenge test in investigating 5-HT1A activity in non-depressed 
alcoholic patients. The discrepancy between PRL and cortisol responses to flesinoxan may be 
linked to the possible activation of cortisol secretion through other 5-HT receptors such as 5-
HT2 receptors while PRL secretion seems to be mainly dependant on 5-HT1A post-synaptic 
receptors (Lee et al., 1991; Pitchot et al., 1995). Until now, few flesinoxan human studies were 
available in psychiatric pathology, most of them concerning depressive disorders, personality or 
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behavioral characteristics (Pitchot et al., 1995; Hansenne et al., 1997; 2000; 2001). Since our 
results are not influenced by the depressive status of the patients, it can be hypothesized that 
this neuroendocrine challenge test will be of much interest in future investigations about 
alcoholism. As for the main result of this study, larger samples will be needed to confirm the role 
of 5-HT1A receptors in alcoholism. In particular, since this disorder is often associated with 
impulsiveness and/or aggression (especially in type II alcoholics according to Cloninger’s 
typology), a distinction between type I and type II patients should be made in further studies 
using the flesinoxan challenge test. Blunted neuroendocrine responses to 5-HT1A agonist 
ipsapirone have indeed been shown to be correlated with aggression in aggressive populations 
and PRL responses to buspirone showed to be lower in violent compared to non-violent 
parolees. These results were recently replicated by Cleare and Bond who found an inverse 
correlation between 5-HT1A receptor function and aggression (Cleare and Bond, 2000). 
Moreover, lower PRL response to flesinoxan has been reported among patients with borderline 
personality disorder (BPD) with history of suicide attempt compared to BPD patients without 
history of suicide attempt. The implication of an hypo-5-HT functioning in the impulsivity-
alcoholism spectrum tends to be as well illustrated through various studies about suicide in 
alcoholic patients. Low levels of 5-HT and/or 5-HIAA were found in blood and CSF of alcoholic 
subjects who attempted suicide, and it was recently shown that the risk for high lethality 
suicidal behavior was partly dependent on 5-HTT promoter gene polymorphisms (Gorwood et 
al., 2000). On the other hand, abnormalities in 5-HT1A receptors may underlie suicidal behavior 
in depressed patients (Pitchot et al., 1995). Thus, measuring aggressiveness and more generally 
impulsivity while performing the flesinoxan challenge may contribute to illustrate the specific 
implication of 5-HT1A receptors in such aspects of alcoholism. 
Finally, another question rises when observing the blunted responses to flesinoxan compared to 
controls in our sample : is the observed dysfunction of 5-HT1A receptors in our alcoholic 
patients linked to some extend to alcohol craving ? In the last decade, many findings have indeed 
suggested that serotonin may play a role in craving for alcohol (Ciccocioppo, 1999). Based upon 
pharmacological studies showing some effectiveness in reducing alcohol consumption with 
serotonergic agents, it has been hypothesized that the mood-regulating effects of SSRIs are 
responsible for decreasing the need for relief of negative affect and thus craving for alcohol 
(Cornelius et al., 1997). Given the acute and chronic effects of alcohol on 5-HT levels, another 
possibility to explain the relationship between 5-HT and craving could be that individuals with 
constitutionally low serotonin function, as it has been widely observed in chronic alcoholic 
patients, drink to increase serotonergic activity and “self-medicate” themselves against mood 
dysregulation. Anton has suggested that the link between craving and 5-HT abnormalities may 
lie in the obsessional thinking about alcohol consumption experienced by chronic alcoholics 
(Anton, 1996). Converging observations showing a serotonergic dysfunction in obsessive-
compulsive disorder (OCD) and a specific efficacy of serotonergic agents in OCD on one hand 
(Goodman et al., 1990), and similar neuroanatomical findings in both OCD and alcohol 
dependence on the other hand (Anton, 2000), led to the conclusion that a direct link may exist 
between 5-HT and craving. Because they rise many research opportunities, our results may then 
be a first step in the better understanding of the specific relationship between serotonin, and in 
particular its 5-HT1A receptors, and alcoholism. 
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